European equities traded in the US as American depositary receipts were sharply higher late Tuesday morning, rising 2.1% to 1,351.12 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by furniture maker Natuzzi (NTZ) and accommodations booking company trivago (TRVG), which rose 5.2% and 4.9% respectively. They were followed by biopharmaceutical company Genfit (GNFT) and internet browser company Opera (OPRA), which were up 4.1% and 3.5% respectively.
The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and medical device maker EDAP TMS (EDAP), which fell 4.4% and 2.8% respectively. They were followed by telecommunications operator Telefonica (TEF) and pharmaceutical company Ascendis Pharma (ASND), which were down 1.4% and 1.2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which advanced 9.7% and 8.3% respectively. They were followed by biopharmaceutical companies Mereo BioPharma plc (MREO) and Adaptimmune Therapeutics (ADAP), which increased 5.2% and 5% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Akari Therapeutics (AKTX), which lost 4.7% and 4.3% respectively. They were followed by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 2.1% and 1.2% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.